Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Epstein-Barr Virus Infections 6Sarcoma, Kaposi 4Lymphoproliferative Disorders 4Cytomegalovirus Infections 4Nasopharyngeal Carcinoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Glioblastoma 3Multi-centric Castleman's Disease 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2Acquired Immunodeficiency Syndrome 2Waldenstrom Macroglobulinemia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Solid Tumor, Adult 1Sezary Syndrome 1Sarcoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1

Interventions

Cisplatin 127Gemcitabine 71Radiotherapy, Intensity-Modulated 61toripalimab 39Capecitabine 37Docetaxel 36Fluorouracil 35Radiotherapy 24camrelizumab 23Drug Therapy 22nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11tislelizumab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiation 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × Valganciclovir × Clear all
NCT07138989 2025-08-24

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Not yet recruiting
10 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05166577 2025-03-12

Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC

Viracta Therapeutics, Inc.

Phase 1 Terminated
26 enrolled 23 charts
Head & Neck

Nasopharyngeal Carcinoma

NCT02761291 2016-05-16

Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma

Chang Gung Memorial Hospital

Phase 1 Unknown
18 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence, Epstein-Barr Virus Infections, Multiple Acyl Coenzyme A Dehydrogenase Deficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡